The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1133
June 24, 2002
View Complete Issue         Table of Contents 2019 
Yasmin -- an Oral Contraceptive With a New Progestin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Yasmin -- an Oral Contraceptive With a New Progestin
June 24, 2002 (Issue: 1133)
An oral contraceptive (Yasmin - Berlex) containing 3 mg of drospirenone and 30 mcg of ethinyl estradiol is being promoted as having a low incidence of adverse effects.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Yasmin -- an Oral Contraceptive With a New Progestin
Article code: 1133a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.